Abstract:Abstract The mechanisms governing disease-associated chromatin organization and drug selectivity are poorly understood. Our epigenetic drug screening experiments identify two distinct lineage-specific drug-responsive patterns in myeloid leukemia (MDS/AML) cells. We have established multiple MDS/AML cell lines resistant to nucleic acid analogues with different chemical backbones and have demonstrated a clear relationship between drug-resistance and sugar-phosphate backbone. Based on these results, we used various experimental approaches to elucidate leukemia-associated, drug-responsive chromatin structural changes and their underlying mechanisms. Our data demonstrate that hnRNPK, a conserved factor in heterogeneous nuclear RNA-binding protein (hnRNP) complexes, directly interacts with RNA m5C methyltransferases NSUNs/DMNT2 and RNA-polymerase II (pol-II)/CTD9 as well as erythroid vs myeloid lineage-determining transcription factors (TFs) GATA1 and SPI1/PU.1 to form distinct drug-responsive chromatin structures in MDS/AML cells. hnRNP preferentially binds to methylated polypyrimidine RNA sequences to facilitate transcription elongation. Compared to azacitidine-sensitive MDS/AML cells, there is a marked increase in azacitidine-resistant MDS/AML cells in RNA m5C and NUSNs/ DNMT2 associated with a marked increase in the interaction between hnRNPK and active pol-II/CDK9. By employing a newly-developed nascent RNA capturing technology coupled with super-resolution stimulated-emission depletion confocal microscopy, we demonstrate co-localization of hnRNPK with the TFs and active pol-II at nascent RNA sites in MDS/AML cells, further supporting the existence of hnRNPK-mediated drug-responsive transcription and lineage-specific chromatin structures in MDS/AML cells. Our experiments using clinical specimens demonstrate a positive correlation between MDS/AML progression and increase in expression of hnRNPK and RNA m5C methyltransferases, supporting their importance and clinical relevance. Furthermore, knockdown of hnRNPK and RNA 5mC methyltransferases effectively inhibited the growth of MDS/AML cells. In conclusion, our data demonstrate distinct RNA m5C methyltransferases/hnRNPK-mediated chromatin structures that control the growth and drug sensitivity of MDS/AML cells. Based on our data, we propose a novel working model of RNA m5C methyltransferase/hnRNPK-mediated drug-responsive chromatin structure in MDS/AML cells, in which RNA m5C methyltransferases function as the writers of m5C on nascent RNA, and hnRNPK functions as a reader of the RNA m5C and an operator to regulate transcription elongation and gene activation. Such novel chromatin structure-based drug action models and mechanisms may identify new diagnostic and prognostic biomarkers and therapeutic approaches. Note: This abstract was not presented at the meeting. Citation Format: Jason X. Cheng, Li Cheng, Adam Cloe, Yuan Li, Ming Yue, Michelle M. Le Beau, Richard A. Larson, James W. Vardiman. RNA m5C methyltransferases and hnRNPK mediate disease-associated chromatin structure and drug resistance in leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4470. doi:10.1158/1538-7445.AM2017-4470

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Abstract 4470: RNA M5c Methyltransferases and Hnrnpk Mediate Disease-Associated Chromatin Structure and Drug Resistance in Leukemia

High-resolution simulations of chromatin folding at genomic rearrangements in malignant B cells provide mechanistic insights into proto-oncogene deregulation

Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression

Abstract P15: Aberrant Non-canonical NF-κB Signalling Reprograms the Epigenome Landscape to Drive Oncogenic Transcriptomes in Multiple Myeloma

Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia

A Dynamic Rrna Ribomethylome Drives Stemness in Acute Myeloid Leukemia

Global chromatin reorganization and regulation of genes with specific evolutionary ages during differentiation and cancer

Large-Scale Topological Changes Restrain Malignant Progression in Colorectal Cancer

Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis

A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML

Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation

Chromatin Topology Reorganization and Transcription Repression by PML/RARα in Acute Promyeloid Leukemia

Abstract LB-237: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes Duringoncogenic Transformation

Pml-Rara Drives Acute Promyelocytic Leukemia Genesis By Enhanceosome Depletion Leading To 3d Chromatin Reorganization

Impaired Cell Fate Through Gain-of-function Mutations in a Chromatin Reader.

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma

Abstract LB197: Methylation patterns at adjacent CpG sites within enhancers are part of cell identity and are disrupted during malignant transformation

Heterogeneity in chromatin structure drives core regulatory pathways in B-cell Acute Lymphoblastic Leukemia

Abstract 5592: HMGA1 modulates chromatin state and transcriptional networks involved in plasticity in refractory myeloid leukemia